GLPG vs. LEGN, ITCI, VKTX, JAZZ, BPMC, SMMT, OGN, IONS, BBIO, and CYTK
Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include Legend Biotech (LEGN), Intra-Cellular Therapies (ITCI), Viking Therapeutics (VKTX), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), Summit Therapeutics (SMMT), Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), BridgeBio Pharma (BBIO), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical preparations" industry.
Galapagos (NASDAQ:GLPG) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, community ranking, institutional ownership, media sentiment and risk.
In the previous week, Legend Biotech had 10 more articles in the media than Galapagos. MarketBeat recorded 13 mentions for Legend Biotech and 3 mentions for Galapagos. Legend Biotech's average media sentiment score of 0.66 beat Galapagos' score of 0.20 indicating that Legend Biotech is being referred to more favorably in the news media.
Galapagos has higher earnings, but lower revenue than Legend Biotech.
Galapagos has a net margin of -26.25% compared to Legend Biotech's net margin of -135.92%. Galapagos' return on equity of -2.60% beat Legend Biotech's return on equity.
Galapagos has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500.
Galapagos currently has a consensus price target of $34.50, suggesting a potential upside of 28.92%. Legend Biotech has a consensus price target of $81.10, suggesting a potential upside of 77.97%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than Galapagos.
32.5% of Galapagos shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Galapagos received 404 more outperform votes than Legend Biotech when rated by MarketBeat users. However, 65.26% of users gave Legend Biotech an outperform vote while only 64.54% of users gave Galapagos an outperform vote.
Summary
Legend Biotech beats Galapagos on 9 of the 16 factors compared between the two stocks.
Get Galapagos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galapagos Competitors List
Related Companies and Tools
